You or a loved one has been diagnosed with lung cancer (LC). While you may have heard that “sugar feeds cancer” you want to learn the specifics for lung cancers.
The first article linked and excerpted below talks about “glucose dependent” LC. While reducing the glucose in the patient’s diet will be important, studies also confirm the importance of starving the cancer of oxygen and nutrients through the blood supply of the tumor. The second study linked and excerpted below talks about the importance of cutting off the blood supply (anti-angiogenesis) to LC.
While conventional chemotherapy may be one option for you pursue anti-angiogenesis (chemotherapy), please understand that there are evidence-based angiogenic inhibitors. Nutrition and supplementation can also be forms of non-toxic anti-angiogenesis.
I remain in complete remission from my “incurable” blood cancer called multiple myeloma by living an evidence-based yet non-conventional, anti-MM lifestyle. Starving my cancer of blood vessels (angiogenesis) is job 1.
To learn more about evidence-based therapies for lung cancer, please watch the short video below:
Have you been diagnosed with LC? If so, what therapies are you considering? Scroll down the page, post a question or comment and I will reply to you ASAP.
“Squamous cell lung cancers (SqCC), a form of non–small cell lung cancer (NSCLC), are glucose-DEpendent, while adenocarcinoma NSCLC tumors are largely glucose-INdependent, according to an analysis of patient NSCLC tumor samples…
Researchers found “markedly elevated” expression of GLUT1, a glucose transporter, in lung SqCC, suggesting that GLUT1 and tumor sugar dependence could be targets for new drug development against lung SqCC, a malignancy for which management can be notoriously challenging…
Excessive sugar consumption is not only a problem that can lead to complications like diabetes, but also, based on our studies and others, the evidence is mounting that some cancers are also highly dependent on sugar,..”
“In many cancers, including non-small cell lung cancer (NSCLC), tumor angiogenesis pathways have been identified as important therapeutic targets. Angiogenesis is essential in the process of primary tumor growth, proliferation and metastasis…
Bevacizumab and ramucirumab have both led to improvements in OS when added to standard first and second line chemotherapy, respectively. Small incremental gains seen with both bevacizumab and ramucirumab may be further improved upon by incorporating novel agents and treatment strategies…”